Publications

Search our bibliography using the filters on the right-hand side.

Displaying 51 through 83 of 83 publications.

Wilson M, Ziemiecki R, San Antonio B, McDade C, Thomas S, Winfree KB. Analysis of health care resource use costs in the PROCLAIM trial. Poster presented at the IASLC 17th World Conference on Lung Cancer; December 6, 2016. Vienna, Austria.

Wilson M, Wasserman M, Breton MC, McDade C, Earnshaw S, Farkouh R. Potential clinical and economic impact of switching from the 13-valent to 10-valent pneumococcal conjugate vaccine in Canada. Poster presented at the 2016 Canadian Immunization Conference; December 6, 2016. Ottawa, Canada.

Wilson M, Lim J, Gandhi P, Wang C, Sander S, McDade C, Earnshaw S. Economic analysis of oral anticoagulants in the prevention of vascular events in Medicare patients with nonvalvular atrial fibrillation. Poster presented at the 38th Annual North American Meeting of the Society for Medical Decision Making; October 25, 2016. Vancouver, Canada.

Wilson MR, Gutierrez B, Offord S, Blanchette CM, Eramo A, Earnshaw SR, Kamat SA. Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Drugs Context. 2016 Mar 11;5:212273. doi: 10.7573/dic.212273

Wilson MR, Mody R, Ursan I, Carr SM. Cost-effectiveness of vedolizumab compared with conventional therapy and biologics for treatment of moderately to severely active ulcerative colitis in the United States. Poster presented at the 2015 Digestive Disease Week; May 16, 2015. San Diego, CA.

Wilson M, Mody R, Ursan I, Carr S. The budgetary impact of vedolizumab in the management of moderately to severely active ulcerative colitis and Crohn's disease in the United States. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 7, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 21(4a):S57.

Patel J, Coleman A, Wilson M, McDade C, Carr S, Earnshaw S. Budgetary impact on a U.S. health plan after adopting umeclidinium/vilanterol (UMEC/VI) for the management of moderate-to-severe COPD. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 7, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 2015 Apr 7; 21(4a):S55.

Kamat SA, Blanchette C, Wilson MR, Tangirala M, Earnshaw SR, Offord S, Gutierrez B, Eramo A, Baker RA. Healthcare cost savings associated with aripiprazole once-monthly (AOM) treatment among schizophrenia patients with psychiatric hospitalizations prior to AOM treatment initiation. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 3, 2014.

Purser MF, Wilson MR, Mladsi DM, Wu Y. Literature review of economic models for the treatment of parkinson's disease. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 2, 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3):A60. doi: 10.1016/j.jval.2014.03.355

Wilson MR, Gutierrez B, Offord S, Zhao C, Beillat M, Eramo A, Earnshaw SR. Total healthcare cost-offset associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Poster presented at the US Psychiatric & Mental Health Congress; September 2013.

Farkouh RA, Wilson MR, Tarrants ML, Castelli-Haley J, Armand C. Cost-effectiveness of rasagiline compared with first-line early parkinson disease therapies. Am J Manag Care. 2012 May 1;4(3):99-107.

Mladsi D, Curtis S, Bell MJ, Ito T, Wilson M, Aboud M. Resource utilisation and cost of managing adverse events (AEs) associated with highly active antiretroviral therapy (HAART) in patients with HIV-1. Poster presented at the 18th Annual Conference of the British HIV Association; April 1, 2012. Birmingham, UK. [abstract] HIV Med. 2012 Apr 18; 13(SI):17-8.

Hauber AB, Fleischmann J, Lothgren M, Wilson M, Lam A, Dubois D, Sabatowski R. Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective. J Opioid Manag. 2011 Jul 1;7(4):287-96.

Farkouh R, Wilson M, Tarrants ML, Castelli-Haley J, Armand C. Cost-effectiveness of rasagiline compared with other first-line treatment options for early parkinson's disease in the United States. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A369.

Earnshaw SR, Wilson M, Mauskopf J, Joshi AV. Model-based cost-effectiveness analyses for the treatment of acute stroke events: a review and summary of challenges. Value Health. 2009 Jun 1;12(4):507-20.

Farkouh RA, Wilson MR, Tarrants M, Castelli-Haley J, Armand C. Cost-effectiveness of rasagiline versus ropinirole extended release in delaying levodopa in the treatment of early parkinson's disease in the United States. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 21, 2009. [abstract] Value Health. 2009 May; 12(3):A192.

Earnshaw SR, Wilson MR, Dalal AA, Chambers MG, Jhingran P, Stanford R, Mapel DW. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. Respir Med. 2009 Jan 1;103(1):12-21.

Hauber AB, Lam A, Fleishmann J, Wilson MR. European economic evaluation of OROS hydromorphone in the management of severe chronic cancer and non-cancer pain. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece. [abstract] Value Health. 2008 Nov; 11(6):A640.

Fagiolini A, Mauskopf JA, Wilson MR, Harnett J, Sanders KN, Kremer C. Development of a cost-effectiveness model for evaluating treatment of acute mania/mixed mania in bipolar i disorder. Poster presented at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders; February 2008.

Earnshaw SR, Wilson MR, Blanchette C. Cost-effectiveness of salmeterol/fluticasone propionate in the treatment of COPD: estimating the annual number of exacerbations in chronic obstructive pulmonary disease. Poster presented at the Annual Meeting of the American College of Chest Physicians; October 2007.

Earnshaw SR, Wilson MR, Joshi AV. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage over a two-year managed care enrollment period. Poster presented at the 2007 ISPOR 12th Annual International Meeting; May 22, 2007. [abstract] Value Health. 2007 May; 10(2):A182. Previously presented at the 2006 International Stroke Conference.

Earnshaw SR, Okazawa M, Wilson MR, Blanchette C. Estimating the annual number of exacerbations in chronic obstructive pulmonary disease. Poster presented at the International Conference of the American Thoracic Society; May 2007.

Earnshaw SR, Wilson M, Joshi AV. The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgets. Managed Care Interface. 2007 Jan 1;19(11):39-45.

Wilson MR, Van Houtven CH, Stearns S, Clipp EC. Depression and missed work among informal caregivers of older individuals with dementia. J Fam Econ Issues. 2007;28(4):684-98.

Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Stroke. 2006 Nov 28;37(11):2751-8.

Earnshaw SR, Wilson MR, Joshi AV. Budgetary impact analysis of recombinant activated factor vii in the treatment of intracerebral hemorrhage: a US health plan perspective. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A329.

Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage. Poster presented at the 2006 International Stroke Conference; February 17, 2006. [abstract] Stroke. 2006 Nov; 37(11):2751.

Van Houtven CH, Wilson MR, Stearns SC, Clipp E. Depression and missed work among informal caregivers of older individuals with dementia. Poster presented at the AcademyHealth 2006 Annual Research Meeting; June 2006.

Earnshaw SR, Wilson MR, Joshi AV. Short-term cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Value Health. 2006 May 1;9(3):A8.

Earnshaw SR, Joshi AV, Wilson MR. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage: a US managed care perspective. Poster presented at the Academy of Managed Care Pharmacy 18th Annual Meeting; April 7, 2006.

Earnshaw SR, Wilson MR, Joshi AV. Health plan budget impact analysis of recombinant activated factor VII (rFVIIa) in the treatment of intracerebral hemorrhage. Managed Care Interface. 2006;19(11):39-45.

Van Houtven CH, Wilson MR, Clipp EC. Informal care intensity and caregiver drug utilization. Rev Econ Househ. 2005;3(4):415-33.

Pignone M, Earnshaw S, Tice JA, Pletcher M, Wilson M. Aspirin, statins, or both therapies for primary prevention of myccardial infarction: a cost-utility analysis. J Gen Intern Med. 2004 Jan 1;19:121.